Huntington’s Chorea: Etiopathogenetic Foundations, Inheritance Mechanisms, Clinical Symptomatology, Neurobiological Consequences, Therapeutic Strategies, and Dietary Recommendations in the Context of Progressive Neurodegeneration

Huntington’s Disease (Huntington's chorea, HD) is an inherited, progressively debilitating neurodegenerative disorder of the central nervous system. The prevalence in Caucasian populations is estimated at roughly 5 to 10 per 100,000 individuals, representing approximately 30,000 affected persons in the United States and nearly 40,000 across the European Union. Modern predictive genetic assays allow definitive presymptomatic detection decades prior to clinical onset, facilitating proactive neurological monitoring, genetic counseling, and timely multidimensional support.

Huntington's Disease is caused by an unstable expansion of a cytosine-adenine-guanine (CAG) trinucleotide repeat within the first exon of the HTT gene on chromosome 4p16.3. Physiologically, normal alleles harbor between 10 and 26 CAG repeats (up to 35 repeats are clinically unaffected). Alleles bearing 36 to 39 repeats demonstrate reduced penetrance, whereas 40 or more repeats confer full penetrance. The resulting mutant huntingtin (mHtt) contains an elongated polyglutamine tract that misfolds and aggregates, driving transcriptional dysregulation, mitochondrial failure, and selective neuronal death.

Huntington's Disease follows a classic autosomal dominant pattern of transmission: each offspring of an affected parent possesses a 50% statistical probability of inheriting the mutated allele, irrespective of biological sex. A critical genetic hallmark is genetic anticipation—the progressive decline in age of onset and increased severity in successive generations. CAG repeat tract instability is particularly pronounced during male spermatogenesis; paternal transmission frequently amplifies the triplet count, which can trigger juvenile Huntington's disease (the rigid Westphal variant).

The clinical presentation of Huntington’s Disease is defined by a characteristic symptomatic triad: motor, cognitive, and neuropsychiatric abnormalities. Involuntary, non-repetitive choreic movements initially affect the face and extremities, progressing to gait instability and generalized motor ataxia. As neurodegeneration advances, chorea gradually transitions into muscular rigidity, bradykinesia, and dystonia. Cognitively, patients suffer executive dysfunction, impaired working memory, and subcortical dementia. Neuropsychiatric manifestations encompass severe clinical depression with elevated suicide risk, apathy, irritability, and psychotic episodes.

The primary neuropathological epicenter of Huntington’s Disease is the progressive atrophy of the neostriatum (caudate nucleus and putamen) within the basal ganglia, extending into cerebral cortex in later stages. The selective loss of medium spiny GABAergic projection neurons disinhibits the motor thalamus and cortex, producing characteristic choreiform hyperkinesias. The median disease duration from formal motor diagnosis to death spans 15 to 20 years. The most common proximate causes of mortality include aspiration pneumonia secondary to progressive dysphagia, cardiovascular failure, and fall-related trauma.

Currently, there are no approved disease-modifying therapies capable of halting Huntington’s progression; management remains focused on symptomatic pharmacotherapy and supportive rehabilitation. For debilitating choreic hyperkinesias, vesicular monoamine transporter 2 (VMAT2) inhibitors—including tetrabenazine and deutetrabenazine—and atypical neuroleptics (tiapride, olanzapine) constitute frontline pharmacotherapy. Affective symptoms are managed with selective serotonin reuptake inhibitors (SSRIs). Crucial adjuncts include proactive physical therapy, occupational therapy, and early speech and swallow rehabilitation.

Individuals living with Huntington’s Disease contend with pronounced metabolic hypermetabolism driven by relentless choreiform activity and mitochondrial bioenergetic failure, frequently precipitating progressive cachexia. Daily caloric requirements may surge to 4,000–5,000 kcal. Nutritional management requires nutrient-dense, high-calorie meal plans enriched with healthy lipids, quality protein, and micronutrients. As neurogenic dysphagia advances, thickening liquids, pureeing food textures, and ultimately placing a percutaneous endoscopic gastrostomy (PEG) tube becomes necessary to guarantee safety and prevent fatal aspiration.